IE
VRDN icon

Israel Englander’s Viridian Therapeutics VRDN Stock Holding History

Israel Englander’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,000
Closed -$714K – 6615
2023
Q2 		$714K Buy
+30,000
New +$769K ﹤0.01% 4299

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Israel Englander's VRDN Position: Q2 2026 in Review

Israel Englander sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 140,595 shares — an estimated $2.75M sold.

Israel Englander first reported a position in VRDN in Q1 2017 and held it in 30 quarters. The position peaked at $31.8M in Q2 2023. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Israel Englander reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 140,595 Viridian Therapeutics shares in Q2 2026, an estimated $2.75M.
  • Israel Englander first reported a position in Viridian Therapeutics in Q1 2017 and held it in 30 quarters.
  • Israel Englander's Viridian Therapeutics position peaked at $31.8M in Q2 2023.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.